Ana Jacobowski

Prof. Dr. Ana Jacobowski

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
LALeonardo Recena Aydos
Leonardo Recena Aydos
LALuane Aparecida do Amaral
Luane Aparecida do Amaral
RSRoberta Serafim de Souza
Roberta Serafim de Souza
AJAna Jacobowski
Ana Jacobowski
ESElisvania Freitas dos Santos
Elisvania Freitas dos Santos
MMMaria Ligia Macedo
Maria Ligia Macedo
Researchers have a range of animal models in which to study Nonalcoholic fatty liver disease (NAFLD). Induction of NAFLD by a high-fat diet in the C57BL/6 strain is the most widely used among mice. In this study, we review works that performed NAFLD induction by a high-fat diet using the C57BL/6 strain, focusing on experiments on the effects of lipid ingestion. Studies are initially distinguished into researches in which mice received lipids by oral gavage and studies in which lipid was added to the diet, and each of these designs has peculiarities that must be considered. Oral gavage can be stressful for animals and needs trained handlers but allows accurate control of the dose administered. The addition of oils to the diet can prevent stress caused to mice by gavage, but possible changes in the consistency, taste, and smell of the diet should be considered. Regarding the experimental design, some variables, such as animal sex, treatment time, and diet-related variables, appear to have a definite pattern. However, no pattern was found regarding the number of animals per group, age at the beginning of the experiment, time of adaptation, the substance used as a vehicle, and substance used as a control.

27 July 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AJAna Jacobowski
Ana Jacobowski
ABAna Paula de Araújo Boleti
Ana Paula de Araújo Boleti
MCMaurício Vicente Cruz
Maurício Vicente Cruz
KSKristiane Fanti Del Pino Santos
Kristiane Fanti Del Pino Santos
Lucas Rannier Melo de AndradeLucas Rannier Melo de Andrade
Lucas Rannier Melo de Andrade
MMMaria Ligia Macedo
Maria Ligia Macedo
Antimicrobial resistance (AMR) has emerged as one of the most pressing global health challenges of our time. Alarming projections of increasing mortality from resistant infections highlight the urgent need for innovative solutions. While many candidates have shown promise in preliminary studies, they often encounter challenges in terms of efficacy and safety during clinical translation. This review examines cutting-edge approaches to combat AMR, with a focus on engineered antimicrobial peptides, functionalized nanoparticles, and advanced genomic therapies, including Clustered Regularly Interspaced Short Palindromic Repeats-associated proteins (CRISPR-Cas systems) and phage therapy. Recent advancements in these fields are critically analyzed, with a focus on their mechanisms of action, therapeutic potential, and current limitations. Emphasis is given to strategies targeting biofilm disruption and quorum sensing interference, which address key mechanisms of resistance. By synthesizing current knowledge, this work provides researchers with a comprehensive framework for developing next-generation antimicrobials, highlighting the most promising approaches for overcoming AMR through rational drug design and targeted therapies. Ultimately, this review aims to bridge the gap between experimental innovation and clinical application, providing valuable insights for developing effective and resistance-proof antimicrobial agents.

10 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ABAna Paula de Araújo Boleti
Ana Paula de Araújo Boleti
AJAna Jacobowski
Ana Jacobowski
BFBreno Emanuel Farias Frihling
Breno Emanuel Farias Frihling
MCMaurício Vicente Cruz
Maurício Vicente Cruz
KSKristiane Fanti Del Pino Santos
Kristiane Fanti Del Pino Santos
MMMaria Ligia Macedo
Maria Ligia Macedo
Wound healing is a dynamic process involving distinct phases that are regulated by cellular and molecular interactions. This review explores the fundamental mechanisms involved in wound healing, including the roles of cytokines and growth factors within the local microenvironment, with a particular focus on antimicrobial peptides (AMPs) as immune modulators and therapeutic agents in chronic wounds. Notably, AMPs such as LL-37 have been shown to reduce biofilm density by up to 60%, highlighting their dual role in both modulating host immune responses and combating persistent bacterial infections. It further examines emerging technologies that are transforming the field, extending beyond traditional biological mechanisms to innovations such as smart dressings, 3D bioprinting, AI-driven therapies, regenerative medicine, gene therapy, and organoid models. Additionally, the review addresses strategies to overcome bacterial biofilms and highlights promising approaches including biomaterials, nanomedicine, gene therapy, peptide-loaded nanoparticles, and the application of organoids as advanced platforms for studying and enhancing wound repair.

26 June 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
IEIsabelly Teixeira Espinoça
Isabelly Teixeira Espinoça
DBDenise Caroline Luiz Soares Basilio
Denise Caroline Luiz Soares Basilio
AAAnna Júlia Papa de Araujo
Anna Júlia Papa de Araujo
RORafael Seiji Nakano Ota
Rafael Seiji Nakano Ota
KSKamylla Fernanda Souza de Souza
Kamylla Fernanda Souza de Souza
EPEduardo Benedetti Parisotto
Eduardo Benedetti Parisotto
The study aimed to evaluate the antithrombotic action of Acrocomia aculeata pulp oil (AAPO) in natura, in an in vitro experimental model. AAPO was obtained by solvent extraction, and its chemical characterization was performed by gas chromatography coupled to a mass spectrometer (GC-MS). In vitro toxicity was evaluated with the Trypan Blue exclusion test and in vivo by the Galleria mellonella model. ADP/epinephrine-induced platelet aggregation after treatment with AAPO (50, 100, 200, 400, and 800 μg/mL) was evaluated by turbidimetry, and coagulation was determined by prothrombin activity time (PT) and activated partial thromboplastin time (aPTT). Platelet activation was measured by expression of P-selectin on the platelet surface by flow cytometry and intraplatelet content of reactive oxygen species (ROS) by fluorimetry. The results showed that AAPO has as major components such as oleic acid, palmitic acid, lauric acid, caprylic acid, and squalene. AAPO showed no toxicity in vitro or in vivo. Platelet aggregation decreased against agonists using treatment with different concentrations of AAPO. Oil did not interfere in PT and aPTT. Moreover, it expressively decreased ROS-induced platelet activation and P-selectin expression. Therefore, AAPO showed antiplatelet action since it decreased platelet activation verified by the decrease in P-selectin expression as well as in ROS production.

16 August 2024 in Molecules
Verified
Journal Article
Open access
PDF file
ABAna Paula de Araújo Boleti
Ana Paula de Araújo Boleti
AJAna Jacobowski
Ana Jacobowski
TMTamaeh Monteiro-Alfredo
Tamaeh Monteiro-Alfredo
APAna Paula Ramos Pereira
Ana Paula Ramos Pereira
MOMaria Luiza Oliva
Maria Luiza Oliva
MMMaria Ligia Macedo
Maria Ligia Macedo
Background: Metastatic melanoma stands out as the most lethal form of skin cancer because of its high propensity to spread and its remarkable resistance to treatment methods. Methods: In this review article, we address the incidence of melanoma worldwide and its staging phases. We thoroughly investigate the different melanomas and their associated risk factors. In addition, we underscore the principal therapeutic goals and pharmacological methods that are currently used in the treatment of melanoma. Results: The implementation of targeted therapies has contributed to improving the approach to patients. However, because of the emergence of resistance early in treatment, overall survival and progression-free periods continue to be limited. Conclusions: We provide new insights into plant serine protease inhibitor therapeutics, supporting high-throughput drug screening soon, and seeking a complementary approach to explain crucial mechanisms associated with melanoma.

1 October 2021 in Journal of Medicinal Food
Verified
Journal Article
Closed access
AJAna Jacobowski
Ana Jacobowski
EPEduardo Benedetti Parisotto
Eduardo Benedetti Parisotto
LALeonardo Recena Aydos
Leonardo Recena Aydos
RSRoberta Serafim de Souza
Roberta Serafim de Souza
SVSandra Viveros
Sandra Viveros
MMMaria Lígia Rodrigues Macedo
Maria Lígia Rodrigues Macedo
Acrocomia aculeata fruits are rich in monounsaturated fatty acid, β-carotene, tocopherol, and other antioxidant compounds. The aim of our study was to investigate and compare the protective effects of A. aculeata pulp oil and microencapsulated pulp oil on brain oxidative damage induced by chronic restraint stress (CRS) in rats (cortex, hippocampus, and striatum). Thirty-six Wistar rats were divided into six treatment groups: C, P, and M groups received 1 μL/g of body weight of distilled water, pulp oil, and pulp oil microcapsules by daily gavage, respectively. The SC, SP, and SM groups received 1 μL/g of body weight of distilled water, pulp oil, and pulp oil microcapsules by daily gavage, respectively, and were then subjected to uninterrupted 6 h of CRS. After 21 days of testing, the rats were euthanized and the brain tissue of the groups was removed for evaluation for oxidative damage markers and antioxidant enzymes. Endpoints of oxidative stress (OS) markers (lipid peroxidation, protein carbonylation, and reduced glutathione [GSH]) and antioxidant enzymes (superoxide dismutase and catalase) were evaluated. By imposing chronic stress on rats, pulp oil and microcapsules of pulp oil induced positive antioxidant responses, mainly by increasing the GSH content, increasing the ability of neural tissues to deal with inherent OS, thus protecting against neurodegenerative diseases. The administration of A. aculeata pulp oil and microencapsulated pulp oil made the reversal of the oxidant parameters, which may protect the brain tissue of rats altered by CRS. The Clinical Trial Registration number: n° 1.008/2018 CEUA/UFMS.